Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun Vasant Balar(NYU Langone Health), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), Sanjeev Mariathasan(Kaiser Permanente San Francisco Medical Center), Zachary Boyd(Genesys (United States)), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Petros Grivas(Seattle Cancer Care Alliance), Yohann Loriot(Institut Gustave Roussy), David I. Quinn(USC Norris Comprehensive Cancer Center), Michiel S. van der Heijden(Zorginstituut Nederland), Richard W. Joseph(Daiichi Sankyo (United States)), Ignacio Durán(Instituto de Biomedicina de Sevilla), José Luis Perez‐Gracia(Clinica Universidad de Navarra), Srikala S. Sridhar(Princess Margaret Cancer Centre), Jean Hoffman‐Censits(Sidney Kimmel Comprehensive Cancer Center), Alexandra Drakaki(University of California, Los Angeles), Daniel P. Petrylak(Yale University), Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), David R. Shaffer(Memorial Sloan Kettering Cancer Center), Gregg Fine(Genesys (United States)), Ulka N. Vaishampayan(University of Michigan), Joaquim Bellmunt(Dana-Farber Cancer Institute), Shi Li(Wenzhou Medical University), Edward E. Kadel, Andrea Necchi(Vita-Salute San Raffaele University), Oyewale O. Abidoye, Evan Y. Yu(University of Washington), Bernhard J. Eigl(BC Cancer Agency), Thomas Powles(Queen Mary University of London), Robert Dreicer(University of Virginia), Sandy Srinivas(Stanford University), Priti S. Hegde(Foundation Medicine (United States)), Nancy A. Dawson(University of Maryland, Baltimore), Margitta Retz(Arbeitsgemeinschaft Urologische Onkologie), AnnChristine Thåström, Richard Bourgon
Cited by 2,208
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k